Pre-made Lacutamab benchmark antibody ( Whole mAb, anti-KIR3DL2/CD158k therapeutic antibody, Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lacutamab is a humanised version of anti KIR3DL2 monoclonal antibody clone #1, and has been shown to have potent activity against KIR3DL2-positive tumours.
| Products Name (INN Index) | Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody |
|---|---|
| INN Name | Lacutamab |
| Target | KIR3DL2 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | University of Genoa,Innate Pharma |
| Conditions Approved | NA |
| Conditions Active | Mycosis fungoides,Peripheral T-cell lymphoma,Sezary syndrome |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | KIR3DL2 |
| Package |
